2 top-rated ASX stocks rated at purchase to boost your portfolio


Image source: Getty Images

One thing the Australian equity market has no shortage of are blue chip stocks. But with so many choices, it can be difficult to decide which ones to buy over the others.

To help narrow things down, I’ve selected two top-notch stocks that are considered buys. They are as follows:

The first top-notch ASX action to consider is CSL. It is one of the world’s leading biotechnology companies, comprising the CSL Behring business and the Seqirus business. CSL Behring is the global leader in a US $ 30 billion a year plasma therapy industry. Considering that Seqirus is the second largest player in the global influenza vaccine industry of US $ 6 billion.

While headwinds from COVID-related plasma collection weighed on CSL’s performance, it should only be a temporary headwind. In this context, investors may want to focus more on the long term, which remains very positive for CSL. This is due to its strong portfolio of life-saving therapies and vaccines and its lucrative research and development pipeline.

Morgans is positive on CSL and currently has an additional rating and price target of $ 324.40 on its shares.

Another top-notch ASX stock to watch is Goodman Group. It is a leading integrated commercial and industrial property company with a portfolio of in-demand properties. Many of these properties have exposure to key growth markets such as e-commerce and logistics, which have been a major driver of Goodman’s exceptional performance in recent years.

Fortunately, that strong demand persists today, which has led Goodman to improve its profit guidance for fiscal 2022 this week. Instead of 10% growth, the company now expects growth in operating earnings per share of at least 15%.

It went well with the Citi team. In fact, the broker still believes this direction to be conservative and that Goodman will outperform it. As a result, Citi maintained its buy rating and raised its price target to $ 27.50.


Comments are closed.